16:57 , Feb 13, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs A SNP on PAD4 could help predict the risk of ALS. Genome-wide association studies in 1,955 ALS patients and 28,244 unaffected individuals identified an associations between a SNP on PAD4, SNP (rs2240335), and ALS,...
19:33 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Cell culture and mouse studies suggest promoting CTNNB1 citrullination or PAD2 expression could help treat colorectal cancer. Screening of approved drugs in HEK cell-based assays of CTNNB1 signaling and cell line-based citrullination and...
18:08 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Patient sample, cell culture and mouse studies suggest inhibiting PAD2 could help treat castration-resistant prostate cancer (CRPC). In patient samples, levels of PAD2 were higher in CRPC tumors than in hormone-dependent tumors. In...
22:48 , Mar 9, 2017 |  BC Innovations  |  Finance

Pharmas learn their A, B, seeds

Having stepped in to fill the venture funding void after the financial crisis, corporate VCs are emerging as financing engines for new company formation. Driven largely by the flood of interest in immuno-oncology, pharmas are...
07:00 , Apr 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Peptidyl arginine deiminase type IV (PAD4; PADI4)

Gastrointestinal disease INDICATION: Pancreatitis Mouse studies suggest inhibiting PAD4 could help treat pancreatitis. In a mouse model of inflammatory ductal occlusion pancreatitis, PAD4 knockout decreased fibro-inflammatory remodeling, mesenchymal expansion and other markers of pancreatitis compared with normal...
07:00 , Mar 28, 2016 |  BC Week In Review  |  Company News

Padlock Therapeutics, Bristol-Myers deal

Bristol-Myers will acquire autoimmune company Padlock. The biotech will receive $225 million in upfront and near-term milestone payments and will be eligible for up to $375 million in development and regulatory milestones. Padlock is...
07:00 , Mar 28, 2016 |  BioCentury  |  Finance

Padded coffers

It's still early days for Atlas Venture's first life sciences-only fund, but don't be surprised if the firm starts putting more money to work with smaller syndicates. Atlas wants to make sure it has an...
00:58 , Mar 24, 2016 |  BC Extra  |  Top Story

BMS acquiring Padlock

Bristol-Myers Squibb Co. (NYSE:BMY) will acquire autoimmune play Padlock Therapeutics Inc. (Cambridge, Mass.) for $225 million in upfront and near-term milestone payments. Padlock shareholders are eligible for $375 million in additional development and regulatory milestones....
07:00 , Jul 30, 2015 |  BC Innovations  |  Translation in Brief

Cutting the net

A pathway connecting cholesterol, neutrophils, and macrophages in atherosclerotic plaques could yield new targets for the disease. While a group from the University of Virginia believes the role of immune cells in atherosclerotic plaques has been...
07:00 , Jul 9, 2015 |  BC Innovations  |  Product R&D

Downstream without a NET

ModiQuest B.V. has discovered that its therapeutic mAb against citrullinated histones has the potential to treat autoimmune diseases by inhibiting the formation of neutrophil extracellular traps that play a role in the pathogenesis of autoimmunity....